Physician profile
Craig E Munger
NPI 1922005883
$667.02
in general payments reported to CMS, 2019-2025
9 companies · $60.66 in 2025
The $60.66 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.62 · 2020: $162 · 2021: $155 · 2022: $136 · 2023: $62.66 · 2024: $32.70 · 2025: $60.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $427.21 | 2019-2023 | Tepezza |
| Allergan, INC. | $57.75 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $43.84 | 2024-2025 | Tecnis Iol |
| Sight Sciences, INC. | $36.20 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $34.26 | 2022-2023 | Clareon |
| Sun Pharmaceutical Industries INC. | $24.87 | 2020 | |
| Shire North American Group INC | $15.30 | 2019 | |
| Oyster Point Pharma, INC. | $14.27 | 2022 | |
| Amgen INC. | $13.32 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Munger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.